Denise Rodriguez

Icahn School of Medicine at Mount Sinai — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

7h-index969citations27works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

vaccines and immunoinformatics approaches(17), Immunotherapy and Immune Responses(16), Monoclonal and Polyclonal Antibodies Research(13), SARS-CoV-2 and COVID-19 Research(6), COVID-19 Clinical Research Studies(5)

Publications27 total

T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome
iScience·2025· 1 citedOpen Access
Supplementary Table5 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig4+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supplementary Table3 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig3 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig2 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Data from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig6+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supplementary Table4 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig7+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025· 1 citedOpen Access
Supplementary Table1. from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supplementary Table2 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig5+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
Supp Fig1+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
2025Open Access
PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Cancer Discovery·2025· 12 cited
T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome.
2024· 2 citedOpen Access
Abstract CT108: Immunogenicity of Poly-ICLC matured dendritic cells as an adjuvant for NY-ESO-1 and Melan-A-MART-1 peptide vaccination compared to Montanide® ISA-51 VG, in study subjects with melanoma in complete clinical remission but at high risk of disease recurrence
Cancer Research·2022· 2 cited
Transfusion reactions associated with <scp>COVID</scp>‐19 convalescent plasma therapy for <scp>SARS‐CoV</scp>‐2
Transfusion·2020· 20 cited
Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma
The Journal of Allergy and Clinical Immunology In Practice·2020· 87 citedOpen Access
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study
Nature Medicine·2020· 493 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Nina Bhardwaj(17), Julia Kodysh(16), Cansu Cimen Bozkus(16), Daniela Delbeau-Zagelbaum(16), Mansi Saxena(15), Anna Kaminska(15), Marcia Meseck(15), Timothy J. O’Donnell(15), John Mandeli(15), Sacha Gnjatic(15), Philip Friedlander(15), Thomas U. Marron(14), John P. Finnigan(14), Sayali Onkar(14), Kevin Tuballes(14), Ruiwei Guo(14), Robert Sebra(14), Samir Parekh(14), Matthew D. Galsky(14), Ana Blasquez(14)